


## Glycopyrronium tosylate

## Chemical Properties

CAS No. :	1624259-25-1
Formula:	C <sub>26</sub> H <sub>37</sub> N <sub>0</sub> S <sub>1</sub>
Molecular Weight:	507.64
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Glycopyrronium tosylate an anticholinergic compound used in the treatment of axillary hyperhidrosis for the study of a variety of cryptobacterial tumors.
Targets(IC50)	Others
In vivo	Glycopyrronium tosylate (GT) reduced sweating severity and production versus vehicle and was generally well tolerated. Improvement was substantially greater for GT than for vehicle at every study week, and, at week 4, ASDD scores improved from baseline by 62.6 versus 34.0% (severity), 65.5 versus 40.3% (impact), and 65.4 versus 39.0% (bothersomeness). Improvements favoring GT versus vehicle also occurred for WI items, PGIC, HDSS, and DLQI.[2]

## Solubility Information

Solubility	DMSO: 45 mg/mL (88.65 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9699 mL	9.8495 mL	19.699 mL
5 mM	0.394 mL	1.9699 mL	3.9398 mL
10 mM	0.197 mL	0.9849 mL	1.9699 mL
50 mM	0.0394 mL	0.197 mL	0.394 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Yokozeki H, et al. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study. *J Dermatol.* 2022;49(1):86-94.

Pariser DM, et al. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. *Am J Clin Dermatol.* 2019;20(1):135-145.

Pariser DM, et al. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis. *Clin Pharmacokinet.* 2021;60(5):665-676.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481